CK2-NCoR signaling cascade promotes prostate tumorigenesis

Oncotarget

Volumn 4, Issue 7, 2013, Pages 972-983

  Yoo, Jung Yoon ^a   Lim, Beom Jin ^a   Choi, Hyo Kyoung ^a   Hong, Soon Won ^a   Jang, Ho Sung ^a   Kim, Changsoo ^a   Chun, Kyung Hee ^a,b   Choi, Kyung Chul ^c   Yoon, Ho Geun ^a  

^a Yonsei University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

CK2a; IP 10; NCoR; Prostate cancer; Transcriptional regulation

Indexed keywords

CASEIN KINASE II; EMODIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HISTONE DEACETYLASE 3; MESSENGER RNA; NUCLEAR RECEPTOR COREPRESSOR; PROTEIN C FOS; PROTEIN C JUN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CHROMATIN IMMUNOPRECIPITATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE CONTROL; GENE REPRESSION; HISTOPATHOLOGY; HUMAN; PROMOTER REGION; PROSTATE CANCER; PROSTATE CARCINOGENESIS; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; CARCINOGENESIS; CASEIN KINASE II; CELL LINE, TUMOR; CO-REPRESSOR PROTEINS; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84884229933     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1020     Document Type: Article

References (44)

1. Ahmed K, Issinger OG and Niefind K. Protein kinase CK2: a catalyst for biology, medicine and structural biochemistry. Molecular and cellular biochemistry. 2011; 356(1-2):1-3.
2. Hessenauer A, Schneider CC, Gotz C and Montenarh M. CK2 inhibition induces apoptosis via the ER stress response. Cellular signalling. 2011; 23(1):145-151.
3. Wang G, Ahmad KA, Harris NH and Ahmed K. Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells. Molecular and cellular biochemistry. 2008; 316(1-2):91-97.
4. Ahmad KA, Wang G, Unger G, Slaton J and Ahmed K. Protein kinase CK2--a key suppressor of apoptosis. Advances in enzyme regulation. 2008; 48:179-187.
5. Wang G, Unger G, Ahmad KA, Slaton JW and Ahmed K. Downregulation of CK2 induces apoptosis in cancer cells--a potential approach to cancer therapy. Molecular and cellular biochemistry. 2005; 274(1-2):77-84.
6. Yamane K and Kinsella TJ. CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation. Cancer research. 2005; 65(10):4362-4367.
7. Channavajhala P and Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene. 2002; 21(34):5280-5288.
8. Romieu-Mourez R, Landesman-Bollag E, Seldin DC and Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer research. 2002; 62(22):6770-6778.
9. Unger GM, Davis AT, Slaton JW and Ahmed K. Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Current cancer drug targets. 2004; 4(1):77-84.
10. Li D, Dobrowolska G, Aicher LD, Chen M, Wright JH, Drueckes P, Dunphy EL, Munar ES and Krebs EG. Expression of the casein kinase 2 subunits in Chinese hamster ovary and 3T3 L1 cells provides information on the role of the enzyme in cell proliferation and the cell cycle. The Journal of biological chemistry. 1999; 274(46):32988-32996.
11. Landesman-Bollag E, Song DH, Romieu-Mourez R, Sussman DJ, Cardiff RD, Sonenshein GE and Seldin DC. Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Molecular and cellular biochemistry. 2001; 227(1-2):153-165.
12. Wang J, Gong S and Liu Y. [The expressions of protein kinase CK2alpha in squamous cell carcinoma of larynx and its clinical significance]. Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology. 2006; 20(9):412-414.
13. MacPherson MR, Molina P, Souchelnytskyi S, Wernstedt C, Martin-Perez J, Portillo F and Cano A. Phosphorylation of serine 11 and serine 92 as new positive regulators of human Snail1 function: potential involvement of casein kinase-2 and the cAMP-activated kinase protein kinase A. Molecular biology of the cell. 2010; 21(2):244-253.
14. Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I, Santos A, Silva R, Acevedo B, Lopez E, Falcon V and Alonso DF. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer research. 2004; 64(19):7127-7129.
15. Slaton JW, Unger GM, Sloper DT, Davis AT and Ahmed K. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Molecular cancer research: MCR. 2004; 2(12):712-721.
16. Gotz C, Gratz A, Kucklaender U and Jose J. TF--a novel cell-permeable and selective inhibitor of human protein kinase CK2 induces apoptosis in the prostate cancer cell line LNCaP. Biochimica et biophysica acta. 2012; 1820(7):970-977.
17. Shin S, Lee Y, Kim W, Ko H, Choi H and Kim K. Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. The EMBO journal. 2005; 24(20):3532-3542.
18. Yoo JY, Choi HK, Choi KC, Park SY, Ota I, Yook JI, Lee YH, Kim K and Yoon HG. Nuclear hormone receptor corepressor promotes esophageal cancer cell invasion by transcriptional repression of interferon-gamma-inducible protein 10 in a casein kinase 2-dependent manner. Molecular biology of the cell. 2012; 23(15):2943-2954.
19. Hessenauer A, Montenarh M and Gotz C. Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. International journal of oncology. 2003; 22(6):1263-1270.
20. Wang G, Ahmad KA, Unger G, Slaton JW and Ahmed K. CK2 signaling in androgen-dependent and -independent prostate cancer. Journal of cellular biochemistry. 2006; 99(2):382-391.
21. Orzechowska E, Kozlowska E, Staron K and Trzcinska-Danielewicz J. Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human. Oncology reports. 2012; 27(1):281-285.
22. Yao K, Youn H, Gao X, Huang B, Zhou F, Li B and Han H. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. The Prostate. 2012.
23. Chen JD and Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995; 377(6548):454-457.
24. Privalsky ML. Regulation of SMRT and N-CoR corepressor function. Current topics in microbiology and immunology. 2001; 254:117-136.
25. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J and Wong J. Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. The EMBO journal. 2003; 22(6):1336-1346.
26. Shang Y, Myers M and Brown M. Formation of the androgen receptor transcription complex. Molecular cell. 2002; 9(3):601-610.
27. Kang Z, Janne OA and Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol. 2004; 18(11):2633-2648.
28. Yuan X and Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urologic oncology. 2009; 27(1):36-41.
29. Battaglia S, Maguire O, Thorne JL, Hornung LB, Doig CL, Liu S, Sucheston LE, Bianchi A, Khanim FL, Gommersall LM, Coulter HS, Rakha S, Giddings I, O'Neill LP, Cooper CS, McCabe CJ, et al. Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. Carcinogenesis. 2010; 31(9):1650-1660.
30. Ting HJ, Bao BY, Reeder JE, Messing EM and Lee YF. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. Molecular cancer research: MCR. 2007; 5(9):967-980.
31. Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL and Cochet C. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer. 2007; 43(5):928-934.
32. Cersosimo RJ. New agents for the management of castration-resistant prostate cancer. The Annals of pharmacotherapy. 2012; 46(11):1518-1528.
33. Tsao CK, Galsky MD, Small AC, Yee T and Oh WK. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU international. 2012; 110(11):1580-1588.
34. Wegiel B, Evans S, Hellsten R, Otterbein LE, Bjartell A and Persson JL. Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Current cancer drug targets. 2010; 10(4):392-401.
35. Heinlein CA and Chang C. Androgen receptor (AR) coregulators: an overview. Endocrine reviews. 2002; 23(2):175-200.
36. Trembley JH, Wang G, Unger G, Slaton J and Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cellular and molecular life sciences: CMLS. 2009; 66(11-12):1858-1867.
37. Mascia F, Mariani V, Girolomoni G and Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol. 2003; 163(1):303-312.
38. Pastore S, Mascia F, Mariotti F, Dattilo C, Mariani V and Girolomoni G. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol. 2005; 174(8):5047-5056.
39. Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, Fang B, Fang X, Fang D, Litchfield DW, Aldape K and Lu Z. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell. 2009; 36(4):547-559.
40. Gan Y, Shi C, Inge L, Hibner M, Balducci J and Huang Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene. 2010; 29(35):4947-4958.
41. Jonas BA and Privalsky ML. SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways. The Journal of biological chemistry. 2004; 279(52):54676-54686.
42. Radhakrishnan R, Solomon M, Satyamoorthy K, Martin LE and Lingen MW. Tissue microarray - a high-throughput molecular analysis in head and neck cancer. J Oral Pathol Med. 2008; 37(3):166-176.
43. Mino N, Takenaka K, Sonobe M, Miyahara R, Yanagihara K, Otake Y, Wada H and Tanaka F. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol. 2007; 95(3):250-257.
44. Yoon HG, Chan DW, Reynolds AB, Qin J and Wong J. N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. Molecular cell. 2003; 12(3):723-734.